From Fins to Silicon: Evolution in the Age of Abundance and Designed Intelligence
Four billion years ago, chemistry learned to copy itself. Everything since—animals, nervous systems, civilizations, the phone in your pocket—traces back to that one accident. We are in a moment where the rules of that process are changing underneath us. The FDA approved the first gene-editing therapy for sickle cell in December 2023. Genetically edited pig kidneys were transplanted into living human patients in 2024. Brain implants are enabling thought-controlled interfaces. Labs are reversing aging hallmarks in animal tissue. For the first time in four billion years, one of evolution’s products has started redesigning the process itself.
This piece traces how we got here from the bottom up: the physics of why life exists, the rare jumps that changed everything (eukaryotes, multicellularity, language), how culture started rewriting biology (lactase persistence, niche construction), and what has actually changed in the last hundred years—developmental plasticity, epigenetics, and an information environment that now shapes cognition at unprecedented scale. Abundance has switched the survival filter nearly off; selection migrated to reproduction timing, partner choice, and social structure. Mismatch is the defining problem: bodies shaped by scarcity and threat now run in environments of surplus and chronic low-intensity stress.
The transition now: we can generate specific variation intentionally and impose designed selection rather than environmental filtering. CRISPR moved from 2012 to clinical reality; Casgevy and gene-edited organs are here. Embryo selection via polygenic scores compresses what would take natural selection many generations into a single decision. Rejuvenation is moving from rhetoric to trials—senolytics, partial reprogramming, first-in-human IND in 2026. Brain–computer interfaces (Neuralink, Synchron, Precision) are in human trials. AI is functioning as an external cognitive layer. Biology is becoming computable (AlphaFold 3, ESM3, Isomorphic Labs, Ginkgo). Life 3.0—able to redesign both hardware and software—is no longer metaphor.
The question that is now ours to answer: when intelligence can redesign its own substrate, is it still evolution? Technically yes; the mechanism is what matters, and it’s different. We are the first things that can look at the process and ask what it should be doing next. We are mostly using that capacity to argue about safety trials and reimbursement while the deeper question—what kind of beings do we want to become, and who gets a say—gets answered by default through a thousand incremental decisions. The honest answer is we haven’t chosen an objective. We’re running the most consequential optimization in the history of life and the objective function is basically whatever the market will pay for and regulators will approve. The answer, if there is one, is to treat the question seriously: with the same attention to mechanism, evidence, and second-order effects that the best scientists bring to their research. What we do with that is, for the first time, genuinely up to us.